Abivax Shares Jump 3.91% After $920 Million Stock Offering Grows Beyond Expectations

Abivax shares climbed 3.91% on Nasdaq on July 2, 2026, after the French biotech confirmed its $920 million American Depositary Share offering. Underwriters exercised their full option, pushing gross proceeds well past the original $600 million target. The ADS offering priced at $125.00 apiece on July 1. Abivax (Nasdaq: ABVX, Euronext Paris: ABVX) said the deal was highly oversubscribed. On Euronext Paris, shares traded at €121.50, up 3.40% from a prior close of €117.50. The company plans to use proceeds for obefazimod’s US launch and ongoing clinical work.

Abivax Shares Rally on Nasdaq After Offering Upsize

Abivax shares (ABVX) gained momentum after underwriters bought an additional 960,000 ADSs. That exercise raised total proceeds from $800 million to $920 million. The base offering covered 6.4 million ADSs, priced at $125.00 each. Demand outpaced the original $600 million target announced on June 30. Trading in the ordinary shares on Euronext Paris was halted during the process. It resumed at 3:30 p.m. CEST on July 1, once pricing was set. The stock’s five-day gain now stands at 50.93%, reflecting strong buyer interest across both listings.

How the $920 Million Deal Came Together

The offering launched small and grew fast. Abivax first sought roughly $600 million on June 30, 2026. Strong demand pushed the size to $800 million by the pricing date. Underwriters then exercised their full 15% option on July 2. That brought gross proceeds to $920 million, or about €807.4 million. A 60-day lock-up now applies to the company, its board, and its executive officers. This restricts insider share sales through early September 2026, subject to standard exceptions.

What’s Driving Investor Confidence in Abivax

Clinical data set the stage for this rally. On June 29, 2026, Abivax reported positive ABTECT Maintenance Part 2 results for obefazimod. The data covered refractory ulcerative colitis patients and reinforced the drug’s safety profile. Analysts responded quickly:

• Jefferies upgraded Abivax to Buy after the fresh trial data.
• Eight analysts now hold a consensus Buy rating on ABVX.
• The average price target sits at €120.06, near current levels.
• Reuters reported Abivax nearing an $11 billion valuation after the raise.

Peers like Structure Therapeutics and Apogee Therapeutics trade in the same biotech space, though neither matches this month’s volatility.

Cash Runway and Use of Proceeds

Abivax held €491.6 million ($560.13 million) in cash and short-term investments as of March 31, 2026. Combined with the new $920 million raise, management expects funding into the second quarter of 2029. Proceeds will support US commercialization of obefazimod, the company’s lead drug candidate for ulcerative colitis. Additional funds go toward Crohn’s disease research and general corporate needs. Obefazimod remains in Phase 3 trials for ulcerative colitis and Phase 2b trials for Crohn’s disease.

Final Thoughts

Abivax shares have had an eventful week, swinging from a $600 million target to a $920 million close. Strong clinical data and heavy investor demand pushed both the offering size and the stock price higher. With extended cash runway into 2029, the company now has room to advance obefazimod toward commercialization. Investors will likely watch upcoming trial readouts and Q2 2026 earnings, expected soon, for the next catalyst.

Disclaimer:

The content shared by Meyka AI PTY LTD is solely for research and informational purposes. Meyka is not a financial advisory service, and the information provided should not be considered investment or trading advice